Oslo, Norway, 25 March 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that the Company on Thursday 28 March 2019 13:00 (CET) will hold a live Q&A session with Targovax’s senior management.
The Q&A session will streamed at Aksjeforum. Please follow this link: http://bit.ly/2HPDTd5
We welcome questions before and during the session. Please send questions in advance to contact@targovax.com or post them in the commentary field below the stream during the Q&A-session.
The session will be held in Norwegian.
- Date: Thursday 28 March 2019
- Time: 13:00 CET
- Presenters: CEO Øystein Soug and CFO Torbjørn Furuseth
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum – Corporate Communications
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102’s targeted path-to-market indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma, is expected to produce important proof-of-concept immune activation data in heavily pre-treated patients.
Targovax is also developing a neo-antigen cancer vaccine targeting tumors with oncogenic RAS–mutations, which are known to drive cancer. The TG vaccine program has shown strong RAS-specific immune activation and a signal of clinical efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently tested in a phase I trial in colorectal cancer, both as monotherapy and in combination with Keytruda (an anti-PD1 check point inhibitor).
About Zelluna Immunotherapy
Zelluna Immunotherapy specializes in immunotherapies targeting a broad range of solid cancers with a high unmet medical need. The company is developing a unique portfolio of non-engineered tumor specific T-cell receptors (TCRs) isolated from long-term surviving patients from cancer vaccine trials. The TCRs combine specificity and affinity to have the potential for a safe and efficient therapy to target a variety of common cancer types. Zelluna, in addition to internal competences, has a long-term agreement with the Department for Cell Therapy at Oslo University Hospital, providing comprehensive capabilities of TCR development, ranging from lead discovery to clinical translation.